Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients

Completed

Conditions: Platelet Aggregation Inhibitors

First Posted Date: 2016-03-17

Last Posted Date: 2016-03-18

Lead Sponsor: National Cerebral and Cardiovascular Center, Japan

Target Recruit Count: 518

Registration Number: NCT02711410

Genotyping Influences Outcome of Coronary Artery Stenting

Not Applicable

Completed

Conditions: CLOPIDOGREL, POOR METABOLISM of (Disorder)
Myocardial Ischemia

Interventions: Drug: Clopidogrel

First Posted Date: 2016-03-14

Last Posted Date: 2016-03-14

Lead Sponsor: Korea University Anam Hospital

Target Recruit Count: 5000

Registration Number: NCT02707445

High On-treatment Platelet Reactivity Identified by Multiple Platelet Function Assay

Not Applicable

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2016-03-04

Last Posted Date: 2016-03-04

Lead Sponsor: Wuhan Asia Heart Hospital

Target Recruit Count: 477

Registration Number: NCT02699008

Locations: 🇨🇳
Wuhan Asia Heart Hospital, Wuhan, Hubei, China

Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI

Phase 4

Conditions: Female , Infertility

Interventions: Drug: placebo
Drug: clopidogrel
Drug: enoxaparin

First Posted Date: 2016-03-02

Last Posted Date: 2016-03-02

Lead Sponsor: Ain Shams Maternity Hospital

Target Recruit Count: 150

Registration Number: NCT02696330

Locations: 🇪🇬
Ain Shams maternity hospital, Cairo, Egypt

Ticagrelor Versus Clopidogrel in Carotid Artery Stenting

Phase 2

Completed

Conditions: Carotid Artery Stenosis

Interventions: Drug: Ticagrelor
Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2016-02-09

Last Posted Date: 2022-06-28

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 210

Registration Number: NCT02677545

Locations: 🇨🇭
Kantonsspital Aarau Klinik für Neurologie, Aarau, Switzerland
🇮🇹
Ospedale Civile di Mirano, Department of Cardiology, Mirano, Italy
🇧🇪
Ghent University Hospital - Dept thoracic and vascular surgery, Ghent, Belgium

and more 12 locations

Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm

Phase 3

Completed

Conditions: Cerebral Aneurysm

Interventions: Drug: Clopidogrel
Drug: Ticagrelor
Drug: aspirin

First Posted Date: 2016-02-05

Last Posted Date: 2021-07-16

Lead Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

Target Recruit Count: 100

Registration Number: NCT02675205

Locations: 🇫🇷
Fondation Ophtalmologique Adolphe de Rothschild, Paris, France

A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction

Phase 4

Completed

Conditions: Myocardial Infarction
Diabetes Mellitus
Coronary Artery Disease
Renal Disease

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2016-01-26

Last Posted Date: 2017-07-18

Lead Sponsor: University of Patras

Target Recruit Count: 20

Registration Number: NCT02663713

Locations: 🇬🇷
Cardiology Department Patras University Hospital, Rio, Achaia, Greece

Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI

Phase 4

Completed

Conditions: Aortic Valve Disease
Myocardial Infarction
Stroke
Bleeding

Interventions: Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2015-12-29

Last Posted Date: 2018-07-17

Lead Sponsor: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec

Target Recruit Count: 222

Registration Number: NCT02640794

Locations: 🇨🇦
St Michael's Hospital, Toronto, Ontario, Canada
🇪🇸
Hospital Vall d'Hebron de Barcelona, Barcelona, Spain
🇨🇦
Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada

and more 1 locations